Abstract: Umbilical cord blood transplant (CBT) has traditionally been associated with slower engraftment of neutrophils, delayed immune reconstitution and consequently higher risk of infections as compared with peripheral blood progenitor cell (PBPC) or bone marrow (BM) transplants. This is primarily due to low numbers of total nucleated cells (TNCs) and the naive nature of CB immune cells. The use of double unit CB transplant (DCBT) increases the total cell dose in the graft, but it still does not produce as rapid engraftment as seen with PBPC or even BM transplants. Herein, we discuss strategies to improve engraftment after CBT. We describe methods of (I) expansion of CB graft ex vivo to increase the total cell dose; and (II) enhancement of BM homing capability of CB progenitor cells; (III) ex vivo expansion of CB derived T cells for improving T cell function against viruses, tumors and protection from graft versus host disease (GVHD). With these novel approaches, engraftment after CBT is now reaching levels comparable to that of other graft types.
Introduction
Despite multiple advantages of umbilical cord blood (CB) transplant (CBT) (1, 2) , it is associated with delayed engraftment and immune reconstitution leading to a greater risk of infections and graft rejection as compared with bone marrow (BM) or peripheral blood (PB) grafts (3) (4) (5) (6) . For instance, after myeloablative conditioning, neutrophil engraftment is achieved in about 20-30 days with unmanipulated CBT as compared to 10-20 days after PB and 15-25 days after BM transplant (7) (8) (9) (10) (11) (12) (13) . This is partly explained by lower numbers of total nucleated cells (TNCs) and CD34 + cells in a CB graft, which are typically only about 5-10% of the doses available for PB or BM stem cell transplant (SCT) (7) (8) (9) (10) (11) (12) (13) . The minimum recommended TNC dose is 2.5×10 7 -3×10 7 /kg for 5-6/6 matched CBT, while higher numbers are needed for greater HLAmismatch.
Several groups have shown that T cell immune reconstitution after double or single CBT (with or without serotherapy) is delayed (14, 15) and this, along with the naivety of the infused CB T cells, correlates with an increased risk of viral reactivation or infection from latent and lytic viruses like cytomegalovirus (CMV), Epstein Barr virus (EBV) and adenovirus in the post-transplantation period (16) (17) (18) . A comparison of immune recovery after double CBT and HLA-matched unrelated donor (MUD) revealed delay in recovery of naive (CD45RO) memory (CD45RO+) CD4 + T cells, CD8 + T cells, and regulatory
Review Article
Engineering cord blood to improve engraftment after cord blood transplant CD4 + CD25 + T cells, which correlates with the increased viral infection in the early post transplantation period (15) . A delayed time to recovery of thymopoiesis has been reported in recipients of UCBT compared with recipients of other graft sources (19) .
With the increasing use of CB as alternative donor, efforts are being made to address the above limitations. One strategy to overcome this is the use of 2 partially HLAmatched CB units, which circumvents the limitation of low cell dose (9) , but it still does not produce rapid engraftment as seen with PB and BM SCT. Another technique is coinfusion of one or two CB units along with CD34 + -selected PB stem cells from HLA-haploidentical donor, known as the "Haplo-Cord" transplant (20) (21) (22) (23) (24) . Two other methods to augment engraftment, which can be employed in the setting of either single or double unit CBT, include ex vivo expansion and/or ex vivo manipulation to improving BM homing ability of CB progenitor cells and immune modulation.
The purpose of this review is to describe the advances in CB engineering to improve CB engraftment and immune reconstitution.
Unique features of CB
It is important to acknowledge the quantitative and qualitative differences in the composition of UCB and hematopoietic stem cells (HSCs) from PB grafts prior to developing strategies for expansion (25) . While UCB contains a higher concentration of HSC than adult PB, each unit contains one to two log lower total cell dose compared to BM and PBSC harvests (26) . Furthermore, the vast majority of T cells within UCB are antigen-inexperienced naïve (CD45RA+), being less responsive to allogeneic stimulation, having reduced expression of transcription factors associated with T-cell activation [e.g., nuclear factor of activated T cells (NFAT)], and producing lower levels of effector cytokines compared to activated T cells from adult PB (27) (28) (29) . The immaturity of UCB dendritic cells is also associated with lower antigen presenting activity, reduced expression of co-stimulatory molecules (CD80, CD86), reduced cytokine production [TNFα, interleukin (IL) -12] , and an inherent ability to induce immune tolerance through peripheral expansion of regulatory T cells (Tregs) (30) .
Ex vivo expansion of CB-derived stem cells
Multiple methods of CB expansion have been testedvarying remarkably from the starting cell population used for expansion (CD34 + versus CD133 + selected), the type of device used for cell extraction (Miltenyi CliniMacs or Nexell Isolex-300i), type of culture media (with or without serum), combination of cytokines [stem cell factor (SCF), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), Fms-like tyrosine kinase 3 ligand (FLT-3L), IL-3, IL-6, IL-11, megakaryocyte growth and differentiation factor (MGDF) and thrombopoietin (TPO)], duration of culture (ranging from 1-10 weeks) and whether or not stromal support is used (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . In addition, the timing of thawing of the CB unit in context of the timing of transplant, and the proportion of CB unit used for expansion also varied considerably.
Static culture technique for CB stem cell expansion
One of the earliest clinical trials assessing the utility of ex vivo expanded CBT was reported by Shpall et al. (42) in the setting of single unit CBT in 37 patients (25 adults, 12 children), following myeloablative total body irradiation (TBI) or busulfan based conditioning. All patients received horse antithymocyte globulin (ATG) 30 mg/kg daily on days −5, −4, and −3. Graft versus host disease (GVHD) prophylaxis was provided with cyclosporine and prednisone. The study was conducted in two strata involving different methods. In the first stratum (n=25), the entire CB unit was thawed on day 0. A part of it (40-60%) was infused on day 0, while the rest was expanded ex vivo and infused on day +10. In the second stratum (n=12), only a fraction of the CB unit to be expanded was thawed (40-60%) on day −10. This portion was set in culture for expansion and infused on day 0 along with freshly thawed rest of the CB fraction. 
Early progenitor cell (EPC) differentiation blockers
Despite modest expansion of cells in the trials mentioned above, failure to accelerate engraftment suggested that there might be potential loss of EPCs during the culture process resulting from differentiation of CD34 + cells to mature lineages (44) . Therefore, methods to block in vitro differentiation of CD34 + cells in an attempt to expand EPCs were explored.
Copper chelators
Severe anemia and neutropenia are well-recognized signs of copper deficiency, resulting from ineffective erythropoiesis and granulopoiesis due to the arrest of progenitor cell maturation (45) (46) (47) . Similar effects can be induced by using a high affinity copper chelator which decreases the intracellular copper content (48 had engraftment from the expanded cord at the time of engraftment while the rest engrafted from the unmanipulated unit. Interestingly, two patients were noted to have longterm persistence of the expanded cells till day 180 and day 240, but not after one year, after which the unexpanded cord completely contributed to engraftment (54) .
Nicotinamide (NAM)
Another method of blocking in vitro differentiation of EPCs is the use of a vitamin B3 analogue-NAM, which inhibits several key enzymes that require NAD+, including the sirtuin family of histone/protein deacetylases (such as SIRT1) that regulate several biological pathways involving cell adhesion, migration, proliferation and differentiation (55) (56) (57) (58) (59) . In preclinical studies, ex vivo treatment of CB CD34 + cells with NAM and cytokines led to their robust expansion (60, 61) . The efficacy of NAM-expanded CBT was then tested in a clinical trial involving 11 adult patients (median age 45 years, median weight 83 kg) in the setting of DCBT after a myeloablative preparative regimen of Flu/Cy/ TBI or Flu/TBI. GVHD prophylaxis was provided by tacrolimus and MMF. One of the CB units was thawed, selected for CD133 + cells and expanded ex vivo for 3 weeks with SCF, TPO, IL-6 and FLT3-L. The negative fraction was re-cryopreserved, and later re-thawed and infused along with the expanded fraction and a second unmanipulated CB unit. Half of the patients engrafted from the expanded unit, one-fourth engrafted with the unexpanded unit and the rest had dual-chimerism from both the units. The expanded CB unit provided long-term engraftment in 8 of 10 evaluable patients, which remained stable for up to 36 months. Acute grade II GVHD occurred in 5 out of 11 patients; there were no cases of grades III-IV acute GVHD and 2 patients developed chronic GVHD (62).
Stem regenin-1 (SR1)
Most recently, Wagner et al. reported the results of CB expansion using SR1 (63) , which directly binds to and inhibits aryl hydrocarbon receptor (which promotes differentiation of EPCs) (64, 65 Other outcomes, including grade II-IV, grade III-IV acute GVHD, transplant-related mortality and overall survival were similar in both the groups.
Mesenchymal stem cell (MSC) supported expansion
Another technique of ex vivo expansion simulates the in vivo growth environment of EPCs by using MSCs during culture, which provides a "niche" for hematopoiesis by producing cytokines and other proteins that regulate hematopoietic cell proliferation as well as homing (66) . Co-culturing with MSCs also prevents the initial cell loss that occurs during the selection process, as it does not require purification of either CD34 + or CD133 + cells (67 of the patients at 6 months while long term engraftment beyond 1-year was provided solely by the unmanipulated unit. The cumulative incidence of grade II-IV acute GVHD (42%), grade III-IV acute GVHD (13%), chronic GVHD (45%) was similar as in the CIBMTR or institutional controls.
Improving homing capacity of CB progenitor cells
Apart from boosting the progenitor cell content of a graft, another mutually non-exclusive technique to augment engraftment involves increasing the capacity of CB progenitor cells to home to BM. Three published trials explored this concept, two of which showed dramatic improvement in engraftment without affecting the cell dose.
Prostaglandin E2 (PGE2) analog
PGE2 stimulates the growth and homing potential of multilineage progenitor cells, which is postulated to be mediated via up-regulation of survivin (apoptosisinhibiting protein) cyclin D1 (proliferation gene) and the chemokine receptor CXCR4 (which promotes adhesion and homing) (70 In cohort 1 (n=9), one of the CB units was incubated with 10 mM of dmPGE2 (fate therapeutics) for 1 hour at 4 ℃. This method was changed after the authors noticed 2 cases of primary graft failure and no improvement in the rates of neutrophil recovery (median 24 days). After conducting a comprehensive genome-wide expression analysis by varying the culture techniques, the authors found that 2-hour incubation with prostaglandin at 37 ℃ was required to induce the maximal activation of the prostaglandin pathway. Therefore, for the second cohort (n=12), they incubated one CB unit in the same solution as above but for 2 hours at 37 ℃. The smaller of the units was treated ex vivo in 6 out of 9 patients in cohort 1, while the larger unit underwent treatment in rest of the patients in cohort 1 and all of the patients in cohort 2. Both the units were thawed on day 0 and infused within 4 hours of each other (larger followed by the smaller unit). .05) was significantly shorter than in the historical controls. All evaluable patients had 100% chimerism on day +30-40% from the fucosylated unit, 40% from the unmanipulated unit and 20% had dual chimerism from both units. There were no differences in neutrophil or platelet engraftment among those who engrafted from fucosylated versus unmanipulated unit. The cumulative incidence of grade II-IV acute GVHD was 40.9%, grade III-IV was 9.1% and chronic GVHD 5%, which were similar to that in controls (74) .
DPPIV inhibitor
Another study examined the efficacy of an oral dipeptidyl peptidase-4 (DPPIV) inhibitor-sitagliptin, which is a commonly used antidiabetic drug. DPPIV/CD26 is a membrane bound peptidase that inhibits the migratory potential of CD34 + cells by cleaving CXCL12/SDF-1α (stromal cell-derived factor 1) at its N-terminal (75 (76) . A clinical trial assessed its safety and efficacy in 24 patients with hematological malignancies who received myeloablative conditioning with TBI (13.2 Gy) and cyclophosphamide (120 mg/kg) followed by single unit CBT. All patients received sitagliptin, 600 mg once daily from day −1 to day +2. The median infused TNC was 2.3×10 7 /kg and the median infused CD34 + dose was 1×10 5 /kg.
The median time to neutrophil engraftment was 21 (range, 13-50) days and that of platelet engraftment was 77 (range, 48-220) days, which are not improved over reported results of unmanipulated CBT (77, 78) .
Expansion of CB derived T cells

Expanding T cells for donor lymphocyte infusion (DLI)
Given the limited cell number and non-availability of donor, the use of DLI to boost post-transplant immunity to prevent infections, treat mixed chimerism and disease relapse is currently restricted to pre-clinical and early phase trials. /kg recipient body weight (81) . In a pilot phase I study, four patients received a CB-derived DLI at a median 87 days (range, 48-137 days) after UCB transplantation (81) . There were no infusion-related toxicities and there was no clinically GVHD arising as consequence of the DLI. In another phase 1 trial by Hexner et al., patients with CB frozen in 2 fractions received ex vivo expanded CB T cells at 1×10 5 cells/kg (82) . There was evidence of early T cell trafficking and supraphysiological levels of cytokines relevant to engraftment. However, the study was stopped early due to grade 3 GVHD in 2/4 patients. Clinical activity of CB derived DLI thus awaits larger study ( Table 1) .
Virus directed T cells Ex vivo expanded virus specific T cells (VSTs)
T cell immune reconstitution is essential to speed up the recover from viral infections. Adoptive T cell therapy using donor-derived ex vivo expanded T cells has emerged as an effective strategy in preventing and treating viral infections (83) (84) (85) . Simplified methods for rapid production of multiVSTs from seropositive individuals have been validated and used for prophylaxis and treatment in the post-transplant setting (86) (87) (88) . There are however a few obstacles to extend this approach to the CB setting. These include: (I) the limited numbers of CB T-cells available for manipulation; and (II) the naivety of CB T cells. Hence, the development of virus-protective T cell therapy for patients undergoing CBT requires the priming and extensive expansion of naive T cells rather than the more limited and simple direct expansion of pre-existing VST populations from virusexperienced donors. As a result, the manufacture of CBderived multi-VSTs requires manufacturing times of 10+ weeks (84) .
Further, CB T-cells have lower cytotoxic activity and higher activation-induced cell death than PB T-cells. These limitations have prevented the production of CB derived VSTs in sufficient numbers for clinical use. Because of these challenges, only a few reports document the generation of antigen-specific T cells from CB. Sun et al. first reported the ability to generate EBV-specific CD4 + T cells using EBV-transformed B-cells, or lymphoblastoid cell lines (LCL) (89). Park et al. then reported the ability to generate CMV-pp65-specific T cells from CB by using CMVimmune complex-loaded DCs, CMV lysate, and IL-12 and IL-7 (90) . Subsequently, our group demonstrated the ability to produce CMV, EBV and adenovirus VSTs from 20% fraction of CB unit using DCs transduced with Ad5f35pp65-vector in presence of IL-7, IL-12 and IL-15 (84) . A clinical trial using CB-derived multi-VSTs for the prevention and treatment of viral infection after CBT was started and completed at BCM. (NCT01017705). On this phase I study 13 patients received VSTs generated from the 20% fraction of a fractionated CB unit. VSTs were infused to 13 patients from 63-443 days post CBT at doses of 5×10 6 to 2.5×10 7 /m 2 (88, 91, 92) . No infusion-related toxicities or GvHD was observed. Within 2 weeks of VST infusion, all patients had detectable virus-specific T cells in their PB that persisted up to 1 year post T-cell infusion (88, 92) . Further, using TCR deep sequencing we have shown that T cell clones present in the VST products of all patients, but not in their PB pre infusion, expand up to 14 fold post infusion. Six patients remain free of CMV, EBV, and Adv reactivation. The patients who developed reactivation had spontaneous resolution or responded to additional dose of VSTs (91). To a v o i d u s i n g a n a d e n o v i r a l v e c t o r, w e t h e n manufactured CB-derived multivirus-specific T cell products using antigen presenting cells (APC) pulsed with clinical grade viral pepmixes spanning Adv (Hexon and Penton), CMV (IE1 and pp65), EBV (LMP2, EBNA1) in the presence of the cytokines. Four patients have received VSTs on this phase 1 study on this phase 1 trial (NCT01923766). By day 45, three patients were virus free and one patient had reduced CMV levels in the detectable but not quantifiable range (88, 93) . Interestingly, epitope mapping showed that the immunodominant CMV-pp65 epitopes recognized by these T cells differed from T cells manufactured from CMV seropositive adult donors, but in preliminary studies still appeared to confer protection (92) .
The above studies however still have the limitations of the lengthy manufacturing time of over 3 months (84) . Strategies to simplify the manufacture method further to reduce the length of manufacture time to 4 weeks and expand the repertoire to multiple viruses such as BKV are underway and hold promise (94) .
TCR-gene modification
An alternative approach to generate virus directed T cells in the naive donor is to transduce T cells with a TCR with known specificity to an HLA restricted epitope identified within an immunogenic viral antigen (95, 96) . Although this strategy offers a novel, rapid method to generate VSTs from naive donors, it is costly and imposes additional regulatory requirements of gene transfer. In addition, the strategy is HLA restricted and targeting a single viral epitope increases the risk of viral immune escape. However, a clinical trial is currently underway in the United Kingdom evaluating T cells transduced with a retroviral vector expressing a CMVspecific TCR for high-risk patients after HSCT (Morris et al.) (97) .
Viral epitope specific T cells
Another group demonstrated that CD34 + CD38
− /low UCBderived HSCs can be differentiated to early T cells using surface-immobilized Notch ligands, which when stimulated with HLA-A*0201 tetramers for CMV and Influenza-A produced functional and viral specific CD8 + T cells (98) .
This method avoids the co-culture with stromal cells as well as retroviral TCR receptors and is another promising method with scalable potential for adoptive T cell transfer.
However, the HLA restriction remains a limitation both for patient eligibility and for the potential for viral immune escape.
HIV-specific T cells
The success of the Berlin patient has stimulated interest in allogeneic-VST therapy for the treatment of HIV (99) .
In a recent report, T cells specific for multiple HIV epitopes, irrespective of donor HLA type, were expanded from seronegative adult donors using DCs pulsed with pepmixes for HIV antigens (100). These T cells suppressed viral replication compared with unexpanded CD8 T cells, and CMV and EBV-specific T cells derived from the same HIV-seronegative donors. This holds promise in the CB setting and HIV-specific T cells manufactured this way are currently studies utilizing donor-derived HIV-specific T cells after allogeneic HSCT are being planned (97) . Moreover, the group at Children's National is currently exploring the potential expanding HIV-specific T cells from CB using a non-HLA restricted GMP compliant approach (101).
Tumor-directed T cells Ex vivo expanded tumor specific T cells
The use of CB-derived antigen-specific T cells, however, is not limited to virus-specific T cells, as highlighted in a study by Merindol et al. (102) . They expanded Melan-A/ MART-1-specific T cells from CB by culturing CBMC with HLA-A2+ LCL pulsed with the HLA-A2-restricted modified Melan-A A27L peptide. The resulting cytotoxic T lymphocyte products exhibited less alloreactivity than T cells generated using the same method derived from the PB of adult donors. PR-1 is a leukemia associated antigen found in PB of patients with myeloid leukemia. St John et al. reported an increased frequency of PR-1 specific CTLs in CB (0.14% of CD8 + T cells), which is 45 times higher than found in PB of healthy adult donor (103). They were then able to expand PR-1 specific T cells from CBMC using peptide pulsed gene modified K562s as artificial APCs that expressed effector memory phenotype and were able to lyse PR-1 specific targets in vitro (103) . The use of a single tumor associated antigen (TAA) peptide limits its application to only well characterized peptide sequences, which in most cases are HLA restricted. Weber et al. developed a strategy to rapidly expand multi-TAA CD4
+ and CD8 + cytotoxic T lymphocytes (TAA-T) from healthy adult donors and CB, regardless of their HLA-type (104) . They used peptide libraries of 15 mer peptides overlapping by 11 amino acids spanning the whole sequence of 5 target antigens Wilm tumor gene1 (WT1), Melanoma associated antigen A3 (MAGE-A3), proteinase 3 (Pr3), human neutrophil elastase (NE) and preferentially expressed antigen in melanoma (PRAME). The TAA-T showed broad reactivity against a multiple target antigens, was polyfunctional and killed primary leukemia blasts in vitro. CB derived TAA-T showed different HLA-restricted epitope specificity compared with adult donor-TAA-T, which will need to be explored in future studies. There was no antigen competition observed and thus other TAA can be easily incorporated to broaden the repertoire of TAAspecific T cells.
Chimeric antigen receptor (CAR) transduced T cells CAR modified T cells targeting tumor antigens have
demonstrated remarkable success in many hematologic malignancies (5, (105) (106) (107) (108) (109) . This approach has also been translated in the CB setting. Micklethwaite et al. demonstrated the feasibility of producing a single product that was virus specific (through native endogenous TCR) and tumor specific (through co-stimulatory molecules from a CD19 + CAR) as an effective antiviral and anti-leukemia therapy after CBT for patients with high risk B-ALL (110) . CD19 + CAR T cells were produced by transducing the VSTs with CD19 retrovirus supernatant at the time of the third stimulation of the VSTs. The resultant CAR-T cells retained viral specificity and lyse CD19 expressing leukemia targets. The same group has also developed a TCR-like antibody that recognizes PR-1/HLA2 complex on acute myeloid leukemia cells and generated a second generation CAR using CBMC (111) . In order to avoid using viral supernatant for transduction, the group at MD Anderson used electro-transfer of non-viral plasmids of the gene of interest (112) . They adapted a Sleeping Beauty transposon and transposase along with artificial APCS to scale up the manufacture of CD19-directed CAR T cells from CBMCs. After 28 days of continuous culture, they were able to generate 10 10 genetically modified T cells for clinical application (112, 113) . The group at Memorial Sloan Kettering expanded CB derived-T cells in presence of IL-12 and IL-15 (114) . These CB T cells were then modified to both express the CD19-specific CAR, 1928z, and secrete IL-12. The 1928z/IL-12 CB T cells retained a central memory-effector phenotype and had increased antitumor efficacy in vitro.
CB derived Tregs
Tregs are a lineage of T cells possessing the ability to inhibit other T-cell responses. Naturally occurring Tregs are CD4 + , CD25 + , express the forkhead box protein 3 (FoxP3) and represent 1-5% of circulating CD4 + T cells (115) . Adoptive transfer of donor Tregs has been explored as a strategy to decrease the severity of acute GVHD and as treatment for chronic GVHD (116) (117) (118) (123) .
Future directions
The techniques for ex vivo expansion have progressed dramatically over time-reforming from the traditional method of cytokine-only static culture to automated continuous perfusion, and then focusing on expansion of EPCs by blocking their ex vivo differentiation using a variety of agents, such as copper chelators, NAM, SR1 or by targeting Notch signaling. However, all of these approaches require several days (up to 3 weeks) of culture before transplant, which adds to the cost and labor. Moreover, some patients may need to proceed to transplant immediately, in which case waiting for 3 weeks may not be ideal. Furthermore, some of these methods which produce enormous expansion of CD34 + cells inevitably lead to a relative state of T cell depletion in the graft-the consequence of which is unclear at this time. Furthermore, all of the current techniques can only be utilized in highly specialized centers, which limits their wider application.
Given the large global inventories of frozen CB units, the development of CB-derived T cell product also provides a novel platform for third party use when adult donors are not readily available (Figure 1) . Adoptive immunotherapy using banked VSTs partially HLAmatched donors has shown considerable success in treating EBV related lymphoma and EBV, adenovirus and CMV infections (124) (125) (126) . The ready availability of clinical grade frozen CB units that are already screened and HLA typed makes CB derived VSTs an attractive and costsaving option. Given the minimal HLA disparity, thirdparty VSTs can be used in non-HSCT setting for oncology patients or for those with primary immune deficiencies. Furthermore, because human leukocyte antigen matching is not required, allogeneic UCB Treg may be a useful strategy for prevention of organ rejection and autoimmune diseases (127) . For therapeutic use, a banking system for UCB Treg would be able to greatly reduce cost and time to transplant. Mckenna et al. have optimized a convenient banking protocol to thaw Tregs that have been frozen down at the end of their first stimulation and restimulate just prior to infusion (127) .
Conclusions
Over the past two decades, tremendous progress has been made to improve the outcomes of CBT by strategies focused on early engraftment, graft engineering and ex vivo expansion of hematopoietic progenitors and immune system cells. Several methods for ex vivo expansion of CB derived T cells for immune modulation have been validated and slowly being brought to the clinic. These strategies hold promise to restore improve outcomes after CBT by enhancing antiviral immunity, preventing GVHD and producing fraction is infused to the patient or manipulated ex vivo to expand CB progenitors. The 20% fraction is used to manufacture ex vivo expanded virus and/or tumor-specific T cells for prophylaxis and treatment of infections, Tregs for GVHD. Antigen specific T cells can be transduced with TCRs or chimeric antigen receptors to direct specificity to viral or tumor specific epitopes. All of these cell types can be generated from frozen cord blood units as a third party source of T cells. This approach can be used to also develop a DLI product to enhance the GVL effect and/or Tregs to treat GVHD. CB, cord blood; VST, virus specific T cell; Treg, regulatory T cell; CAR, chimeric antigen receptor; GVHD, graft versus host disease; TCR, T cell receptor; DLI, donor lymphocyte infusion. 
